A longitudinal study of plasma acylcarnitines throughout pregnancy and associations with risk of gestational diabetes mellitus. Issue 8 (August 2021)

• Record Type: Journal Article
• Authors: Lin, Yuan; Wu, Jing; Zhu, Yeyi; Hinkle, Stefanie N.; Rawal, Shristi; Liang, Liming; Weir, Natalie L.; Tsai, Michael Y.; Zhang, Cuilin
• Is Part Of: Clinical nutrition. Volume 40:Issue 8(2021)
• Page Start: 4863
• Page End: 4870
• Publication Date: 2021-08
• Subjects: Pregnancy -- Gestational diabetes -- Plasma acylcarnitine species -- Longitudinal; GDM gestational diabetes -- BCAA branched-chain amino acid -- BMI body mass index -- ESI-MS/MS electrospray ionization tandem mass spectrometry -- FAO fatty acid oxidation -- GW gestational week -- HDL-C high-density lipoprotein cholesterol -- HOMA-IR homeostatic model assessment of insulin resistance -- LDL-C low-density lipoprotein cholesterol -- LOD limit of detection -- NICHD National Institute of Child Health and Human Development -- OGTT oral glucose tolerance test -- T1D type 1 diabetes -- T2D type 2 diabetes -- SD standard deviation; Critically ill -- Nutrition -- Periodicals; Diet therapy -- Periodicals; Parenteral feeding -- Periodicals; Enteral feeding -- Periodicals; Enteral Nutrition -- Periodicals; Parenteral Nutrition -- Periodicals; Metabolism -- Periodicals; Diétothérapie -- Périodiques; Alimentation parentérale -- Périodiques; Alimentation entérale -- Périodiques; Nutrition -- Périodiques; Diet therapy; Enteral feeding; Nutrition; Parenteral feeding; Electronic journals; Periodicals; Electronic journals; 615.854
• DOI: 10.1016/j.clnu.2021.07.008
• Languages: English
• ISSNs: 0261-5614

Abstract

Summary: Background & aims: Prospective and longitudinal data on the association between acylcarnitines and gestational diabetes (GDM) are lacking. This study aims to prospectively investigate 28 acylcarnitines in relation to subsequent GDM risk. Methods: Within the NICHD Fetal Growth Studies-Singleton Cohort, plasma levels of acylcarnitines and cardiometabolic biomarkers were measured at gestational week (GW) 10–14, 15–26, 23–31, and 33–39 among 107 GDM cases and 214 controls. Results: At GW 10–14, per standard deviation (SD) increased level of C14:1-OH was associated with a 55% increased risk of GDM after adjusting for major risk factors for GDM [OR (95% CI): 1.55 (1.05–2.29)]. At GW 15–26, C4, C8:1 and C16:1-OH were associated with an increased risk of GDM [OR (95% CI) for per SD increase: 1.42 (1.01–2.00), 1.41 (1.02–1.96), and 1.77 (1.10–2.84), respectively]. Whereas increased C10 and C18 were related to lower risk of GDM [OR (95% CI) for per SD increase: 0.74 (0.55–1.00), and 0.69 (0.49–0.97), respectively]. Moreover, we observed correlations of individual acylcarnitine with multiple clinical markers implicated in glucose homeostasis and cardiometabolic function among non-GDM women. Conclusions: Our results demonstrate that several plasma acylcarnitine species are differentially associated with GDM risk by chain length. Future studies are warranted to investigate the distinct roles of individual acylcarnitine in glucose homeostasis in pregnancy.